UBS Group AG - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 163 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.3%.

Quarter-by-quarter ownership
UBS Group AG ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q3 2023$583,286
+2112.4%
21,195
+2627.8%
0.00%
Q2 2023$26,364
-98.8%
777
-98.7%
0.00%
-100.0%
Q1 2023$2,190,282
-58.8%
60,875
-48.9%
0.00%
-50.0%
Q4 2022$5,314,661
+412.0%
119,243
+222.9%
0.00%
Q3 2022$1,038,000
-66.3%
36,928
-67.7%
0.00%
-100.0%
Q2 2022$3,081,000
-43.7%
114,278
-28.9%
0.00%
-50.0%
Q1 2022$5,476,000
+8.5%
160,779
+23.1%
0.00%
+100.0%
Q4 2021$5,046,000
+97.5%
130,590
+175.9%
0.00%0.0%
Q3 2021$2,555,000
+276.3%
47,326
+133.0%
0.00%
Q2 2021$679,000
-39.9%
20,313
-63.0%
0.00%
Q1 2021$1,130,000
+2254.2%
54,849
+1888.7%
0.00%
Q4 2020$48,000
+108.7%
2,758
+75.7%
0.00%
Q3 2020$23,000
+228.6%
1,570
+166.1%
0.00%
Q2 2020$7,000
+600.0%
590
-34.2%
0.00%
Q1 2020$1,000
-66.7%
897
-40.8%
0.00%
Q4 2019$3,000
-70.0%
1,515
-68.1%
0.00%
Q3 2019$10,0000.0%4,747
+35.6%
0.00%
Q2 2019$10,000
+900.0%
3,501
+1641.8%
0.00%
Q1 2019$1,0002010.00%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q2 2022
NameSharesValueWeighting ↓
Kynam Capital Management, LP 3,200,000$88,064,00014.40%
Octagon Capital Advisors LP 759,898$20,912,3933.21%
TSP Capital Management Group, LLC 251,695$6,926,6452.67%
5AM Venture Management, LLC 310,270$8,538,6302.46%
COMMODORE CAPITAL LP 706,665$19,447,4212.27%
ACUTA CAPITAL PARTNERS, LLC 122,341$3,366,8242.26%
Redmile Group, LLC 1,635,938$45,021,0142.14%
RTW INVESTMENTS, LP 3,463,201$95,307,2922.01%
Eversept Partners, LP 588,143$16,185,6951.37%
Affinity Asset Advisors, LLC 150,000$4,128,0001.16%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders